EP Patent

EP3055301B1 — (2-(5-isoindolin-2-yl)pyrimidin-4-yl)-amine derivatives as rho kinase inhibitors for treating autoimmune diseases

Assigned to Kadmon Corp LLC · Expires 2019-11-20 · 6y expired

What this patent protects

Patent listed against belumosudil-mesylate.

Drugs covered by this patent

belumosudil-mesylate (BELUMOSUDIL MESYLATE)

Patent Metadata

Patent number: EP3055301B1
Jurisdiction: EP
Classification: —
Expires: 2019-11-20
Drug substance claim: No
Drug product claim: No
Assignee: Kadmon Corp LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.